Advertisement
ANTX vs XENE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Hold and XENE is a Buy.
ANTX in +21.50% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ANTX advanced for three days, in 199 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANTX's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ANTX as a result. In 62 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ANTX just turned positive on October 27, 2026. Looking at past instances where ANTX's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where ANTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
ANTX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ANTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ANTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.988) is normal, around the industry mean (3.498). P/E Ratio (-3.810) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
XENE's RSI Indicator climbs out of oversold territory
The RSI Indicator for XENE moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 20 of the 26 cases the stock moved higher. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on XENE as a result. In 68 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for XENE just turned positive on October 07, 2026. Looking at past instances where XENE's MACD turned positive, the stock continued to rise in 30 of 49 cases over the following month. The odds of a continued upward trend are 61%.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where XENE advanced for three days, in 189 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for XENE moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XENE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
XENE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XENE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. XENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.053) is normal, around the industry mean (3.498). P/E Ratio (-8.264) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.930) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (588.235) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XENE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ANTX | XENE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 29 Undervalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 81 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 39 | 61 | |
P/E GROWTH RATING 1..100 | 24 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANTX's Valuation (29) in the Managed Health Care industry is somewhat better than the same rating for XENE (76) in the Biotechnology industry. This means that ANTX’s stock grew somewhat faster than XENE’s over the last 12 months.
XENE's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that XENE’s stock grew similarly to ANTX’s over the last 12 months.
XENE's SMR Rating (97) in the Biotechnology industry is in the same range as ANTX (98) in the Managed Health Care industry. This means that XENE’s stock grew similarly to ANTX’s over the last 12 months.
ANTX's Price Growth Rating (39) in the Managed Health Care industry is in the same range as XENE (61) in the Biotechnology industry. This means that ANTX’s stock grew similarly to XENE’s over the last 12 months.
XENE's P/E Growth Rating (12) in the Biotechnology industry is in the same range as ANTX (24) in the Managed Health Care industry. This means that XENE’s stock grew similarly to ANTX’s over the last 12 months.
| ANTX | XENE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 83% | 6 days ago 61% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 70% |
| Advances ODDS (%) | 14 days ago 84% | 2 days ago 67% |
| Declines ODDS (%) | 9 days ago 85% | 29 days ago 68% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANTX’s FA Score shows that 2 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).
- ANTX’s FA Score: 2 green, 3 red.
- XENE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANTX’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).
- ANTX’s TA Score: 4 bullish, 5 bearish.
- XENE’s TA Score: 4 bullish, 5 bearish.
Price Growth
ANTX (@Biotechnology) experienced а +3.59% price change this week, while XENE (@Biotechnology) price change was +8.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.
Reported Earning Dates
ANTX is expected to report earnings on Mar 31, 2027.
XENE is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (-0.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with DNTH. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then DNTH could also see price increases.
| Ticker / NAME | Correlation To ANTX | 1D Price Change % | ||
|---|---|---|---|---|
| ANTX | 100% | +8.25% | ||
| DNTH - ANTX | 40% Loosely correlated | -1.32% | ||
| RLMD - ANTX | 39% Loosely correlated | +3.14% | ||
| XENE - ANTX | 38% Loosely correlated | +2.32% | ||
| SLDB - ANTX | 34% Loosely correlated | +2.14% | ||
| RNAC - ANTX | 31% Poorly correlated | -1.85% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GENW | 14.54 | N/A | N/A |
| Genter Capital International Dividend ETF (GENW) | |||
| REIX | 30.38 | -0.01 | -0.04% |
| NYLIM CBRE Real Estate & Infrastructure ETF (REIX) | |||
| IBDW | 20.19 | -0.10 | -0.52% |
| iShares iBonds Dec 2031 Term Corporate ETF (IBDW) | |||
| GSEE | 62.42 | -0.49 | -0.78% |
| Goldman Sachs MarketBeta Emerging Markets Equity ETF (GSEE) | |||
| IBND | 29.70 | -0.25 | -0.83% |
| State Street SPDR Bloomberg International Corporate Bond ETF (IBND) | |||